Furthermore, Aff-MAG2 specifically targets AML cells that express B7-H3 with high lethal potency and little to no collateral damage, making it a promising candidate for future personalized therapy in AML and other B7-H3-positive malignancies. The gene discussed is CD276; the disease is acute myeloid leukemia.